

**Self-Study Modules On Tuberculosis** 







## Glossary





Centers for Disease Control and Prevention National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention





## U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of Tuberculosis Elimination

> Atlanta, Georgia 2019





## Glossary

acid-fast bacilli (AFB)—mycobacteria that when stained, retain color even after they have been washed in an acid solution; may be detected under a microscope in a stained smear

**adherence to treatment**—following the recommended course of treatment by taking all the prescribed medications for the entire recommended time

**administrative controls**—the first level in the hierarchy of TB infection-control measures; managerial measures that reduce the risk for exposure to persons who have, or might have, TB disease

**adverse reaction**—negative side effect resulting from the use of a drug (for example, hepatitis, nausea, headache)

**AIDS**—acquired immunodeficiency syndrome, a condition in which the immune system is weakened and therefore less able to fight certain infections and diseases; AIDS is caused by infection with the human immunodeficiency virus (HIV)

**airborne infection isolation (AII) room**—formerly called "negative pressure isolation room." A room with special characteristics to prevent the spread of droplet nuclei expelled by a TB patient, including negative-pressure ventilation.

**alveoli**—the small air sacs of the lung that are at the end of the airway; when droplet nuclei reach these air sacs, TB infection begins

**anergy**—the inability to react to a skin test because of a weakened immune system, often caused by HIV infection or severe illness

**antigen**—protein substances that can produce an immune response (such as CFP-10, ESAT-6, or those in PPD)

**antiretroviral therapy (ART)**—a lifelong combination drug treatment to suppress HIV and improve the quality and length of life for a person living with HIV/AIDS

**bacteriologic examination**—tests done in a mycobacteriology laboratory to aid diagnosis of TB disease; includes examining a specimen under a microscope, culturing the specimen, and testing for drug susceptibility

**baseline skin test**—a tuberculin skin test (TST) given to employees or residents in certain facilities when they start their job or enter the facility (see **TB testing program** and **two-step testing**)

**BCG**—bacille Calmette-Guérin (BCG), a vaccine for TB disease that is used in many countries but rarely used in the United States; may cause a false-positive reaction to the TST but does not affect interferon-gamma release assay (IGRA) results

boosted reaction—a positive reaction to a TST, due to a boosted immune response from a skin test given up to a year earlier; occurs in people who were infected a long time ago and whose ability to react to tuberculin has lessened. Two-step testing is used in TB testing programs to tell the difference between boosted reactions and reactions caused by recent infection (see booster phenomenon and two-step testing).

**booster phenomenon**—a phenomenon in which people (especially older adults) who are skin tested many years after becoming infected with *M. tuberculosis* may have a negative reaction to an initial TST, followed by a positive reaction to a TST given up to a year later; this happens because the first TST boosts the immune response. Two-step testing is used in TB testing programs to tell the difference between boosted reactions and reactions caused by recent infection (see **two-step testing**).

**bronchoscopy**—a procedure used to obtain pulmonary secretions or lung tissue with an instrument called a bronchoscope; used only when patients cannot cough up sputum on their own and an induced specimen cannot be obtained

**case management**—a strategy health departments can use to manage patient care and help ensure patients successfully complete treatment

**case rate**—the number of cases that occur during a certain time period, divided by the size of the population during that time period; the case rate is often expressed in terms of a population size of 100,000 persons

**cavity**—a hollow space within the lung, visible on a chest x-ray, that may contain many tubercle bacilli; often occurs in people with severe pulmonary TB disease

**CFP-10**—one of the antigens used in IGRAs that is found in *M. tuberculosis* strains but not in BCG vaccine strains

**civil surgeons**—domestic health care providers who screen immigrants living in the United States and applying for a permanent residence visa or citizenship

**clinical evaluation**—an evaluation done to find out whether a patient has symptoms or signs of TB disease or is responding to treatment; also done to check for adverse reactions to TB medications

clinician—a physician, physician's assistant, or nurse

**colonies**—groups of mycobacteria that have grown on solid media

**congregate setting**—a setting in which a group of persons reside, meet, or gather either for a limited or extended period of time in close physical proximity. Examples include prisons, nursing homes, schools, and homeless shelters.

**contacts**—persons exposed to someone with infectious TB disease; can include family members, roommates or housemates, close friends, coworkers, classmates, and others

**continuation phase**—the period after the first 8 weeks of TB disease treatment, during which tubercle bacilli that remain after the intensive phase are treated with at least two drugs

**control**—a standard of comparison for checking or verifying the results of an experiment

**corticosteroid**—a type of steroid, either natural or manmade, often used to treat arthritis, certain allergies, or other immune disorders

**cough-inducing procedures**—procedures that make a patient cough, such as sputum induction and bronchoscopy

**culture**—to grow organisms in media (substances containing nutrients) so that they or the product of this process can be identified; a positive culture for *M. tuberculosis* contains tubercle bacilli, whereas a negative culture contains no detectable tubercle bacilli

**daily regimen**—a treatment schedule in which the patient takes a dose of each prescribed medication every day

**diabetes mellitus**—a disease in which blood glucose levels are above normal; diabetes can increase susceptibility to some infectious diseases, including TB

**diagnostic evaluation**—an evaluation used to diagnose TB disease; includes a medical history, a chest x-ray, the collection of specimens for bacteriologic examination, and possibly a tuberculin skin test or an interferon-gamma release assay (blood test)

**directly observed therapy (DOT)**—a strategy devised to help patients adhere to treatment; a designated person watches the TB patient swallow each dose of the prescribed drugs to ensure adherence to and tolerability of the regimen

**disseminated TB**—TB disease that occurs when tubercle bacilli enter the bloodstream or lymph system and are carried to all parts of the body where they grow and cause disease in multiple sites, e.g., miliary TB

**droplet nuclei**—very small droplets (1 to 5 microns in diameter) containing *M. tuberculosis* that may be expelled when a person who has infectious TB coughs, sneezes, speaks, or sings; the droplets can remain suspended in the air for several hours, depending on the environment

**drug-resistant**—an organism's ability to grow despite the presence of a particular drug

**drug-resistant TB**—TB caused by *M. tuberculosis* organisms that are able to grow in the presence of a particular drug; TB that is resistant to at least one anti-TB drug

**drug susceptibility pattern**—the list of antituberculosis drugs to which a strain of tubercle bacilli is susceptible and to which it is resistant

**electronic directly observed therapy (eDOT)**—DOT that is delivered remotely (e.g., over a smartphone, tablet, or computer). eDOT can either be real-time or recorded.

**environmental controls**—the second level in the hierarchy of TB infection-control measures; engineering systems used to prevent the transmission of TB in health care settings, including ventilation, high-efficiency particulate air (HEPA) filtration, and ultraviolet germicidal irradiation

**epidemiology**—the study of the distribution and causes of disease and other health problems in different groups of people

**erythema**—redness around the site of the injection when a TST is done; erythema is not measured as part of the reaction size because redness does not indicate that a person has TB infection

**ESAT-6**—one of the antigens used in IGRAs that is found in *M. tuberculosis* strains but not in BCG vaccine strains

**ethambutol (EMB)**—a drug used to treat TB disease; may cause vision problems. Ethambutol should be used cautiously in children who are too young to be monitored for changes in their vision.

**exposure to TB**—time spent with or near someone who has infectious TB disease

**extensively drug-resistant TB (XDR TB)**—a type of MDR TB that is resistant to isoniazid and rifampin, plus resistant to any fluoroquinolone and at least one of three injectable anti-TB drugs (such as amikacin, kanamycin, or capreomycin)

**extrapulmonary TB**—TB disease that occurs in places other than the lungs, such as the lymph nodes, the pleura, the brain, the kidneys, or the bones; most types of extrapulmonary TB are not infectious

**false-negative reaction**—a negative reaction to the TST or IGRA in a person who has TB infection

**false-positive reaction**—a positive reaction to the TST or IGRA in a person who does not have TB infection

**first-line TB treatment drugs**—of the approved drugs to treat TB, isoniazid, rifampin, ethambutol, and pyrazinamide are considered the first-line anti-TB drugs; they form the core of a standard treatment regimen. They are considered "first-line" because together they constitute the most powerful, least expensive, and most tolerable treatment regimen.

## fit check—see user seal check

**fit test**—a method to evaluate the fit of a respirator on a person

**fluoroquinolones**—a class of synthetic broad-spectrum antibacterial drugs. Examples of fluoroquinolones used to treat TB are levofloxacin and moxifloxacin.

**gastrectomy**—a partial or full surgical removal of the stomach

**gastric washing**—a procedure done by inserting a tube through the patient's nose and passing it into the stomach; may be useful for obtaining a specimen for culture from children, who produce little or no sputum when they cough

**GeneXpert**—a semi-automated molecular diagnostic system. See **Xpert MTB/RIF assay**.

**genotype**—distinct genetic pattern of an organism

**genotyping**—a laboratory-based method that can determine the genetic pattern of the strain of *M. tuberculosis* that caused TB disease in a person

**health care facilities**—places where people receive health care, such as hospitals or clinics

**health care personnel**—individuals who work or volunteer in health care settings

health care setting—a place where health care is delivered; examples include inpatient settings, outpatient settings, laboratories, emergency medical services, medical settings in correctional facilities, home-based health care and outreach settings, long-term care facilities, and clinics in homeless shelters

**hepatitis**—inflammation of the liver, causing symptoms such as nausea, vomiting, abdominal pain, fatigue, and brown urine; hepatitis can be caused by several drugs used to treat LTBI or TB disease

**high efficiency particulate air (HEPA) filters**—special filters that can be used in ventilation systems to help remove droplet nuclei from the air

**HIV**—human immunodeficiency virus, the virus that causes AIDS

**immune system**—cells and tissues in the body that protect the body from foreign substances

**immunosuppressive therapy**—therapy that suppresses, or weakens, the immune system

**induced sputum**—sputum that is obtained by having the patient inhale a saline (salt water) mist, causing the patient to cough deeply; this procedure is used to help patients cough up sputum if they cannot do so on their own

**induration**—swelling that can be felt around the site of injection after a TST is done; the reaction size is the diameter of the swollen area, measured across the forearm

**infection control procedures**—measures to prevent the spread of TB

**infectious**—capable of spreading infection; a person who has infectious TB disease expels droplets containing *M. tuberculosis* into the air when he or she coughs, sneezes, speaks, or sings

**infiltrate**—a collection of fluid and cells in the tissues of the lung; visible on a chest x-ray in people with pulmonary TB disease

**intensive phase**—the first 8 weeks of TB disease treatment, during which most of the tubercle bacilli are killed

**interferon-gamma (IFN-γ)**—protein that is normally produced by the body in response to infection. IGRA interpretations are based on the amount of IFN-γ that is released or on the number of cells that release IFN-γ.

**interferon-gamma release assay (IGRA)**—a type of blood test that measures a person's immune reactivity to *M. tuberculosis*. In the United States, the QuantiFERON®-TB Gold Plus (QFT-Plus) and the T-SPOT®. TB test (T-Spot) are currently available IGRAs.

**intermittent therapy**—a treatment schedule in which the patient takes each prescribed medication one, two, or three times weekly at the appropriate dosage

**isolate**—a group of organisms isolated or separated from a specimen; in an *M. tuberculosis* isolate, the organisms have been grown in culture and identified as *M. tuberculosis* 

**isoniazid (INH)**—a drug that is used for treating LTBI and TB disease; although cheap and relatively safe, it may cause hepatitis and other adverse reactions in some patients

**jejunoileal bypass**—surgical operation performed to reduce absorption in the small intestine

**latent TB infection (LTBI)**—refers to the condition when a person is infected with *M. tuberculosis* but does not have TB disease. Persons with LTBI carry the *M. tuberculosis* organism that causes TB, but they do not have TB disease symptoms, do not feel sick, and they cannot spread TB germs to others. Most persons with LTBI have a positive result to the tuberculin skin test or to an interferongamma release assay.

**liver function tests**—tests done to detect injury to the liver, such as hepatitis

**LTBI treatment**—medication that is given to people who have latent TB infection to prevent developing TB disease

malaise—a feeling of general discomfort or illness

Mantoux tuberculin skin test (TST)—a method of testing for TB infection; a needle and syringe are used to inject 0.1 ml (5 tuberculin units) of purified protein derivative (PPD) tuberculin solution between the layers of the skin (intradermally), usually on the forearm; the reaction to this test, usually a small swollen area (induration), is measured 48 to 72 hours after the injection and is interpreted as positive or negative depending on the size of the reaction and the patient's risk factors for TB; the routine methodology for tuberculin skin testing worldwide; supersedes all older methods

**media**—substances containing special nutrients and used for growing cultures of bacteria found in specimens

**medical history**—the part of a patient's life history that is important for diagnosing and treating TB infection or disease, including history of exposure, symptoms, previous diagnosis of TB infection or disease, and risk factors for TB disease

**miliary TB**—a type of disseminated TB disease that occurs when tubercle bacilli enter the bloodstream and are carried to all parts of the body, where they grow and cause disease in multiple sites; the chest x-ray of patients with miliary TB often looks like millet seeds scattered throughout the lung

**mono-resistant TB**—TB that is resistant to one TB treatment drug

**multidrug-resistant TB (MDR TB)**—TB that is resistant to at least the drugs isoniazid and rifampin; MDR TB is more difficult to treat than drug-susceptible TB

**mycobacteria**—a group of bacteria that can cause a variety of diseases

**mycobacteriology laboratory**—a laboratory that deals specifically with *M. tuberculosis* and other mycobacteria

**Mycobacterium avium-complex**—a nontuberculous mycobacteria (NTM) that can cause opportunistic infections in immunocompromised persons; often disseminated infections

**Mycobacterium bovis**—a type of tuberculous mycobacteria that can cause a disease similar to TB; usually infects cows, but it can infect other mammals including humans. Before the pasteurization of milk became common practice, these mycobacteria were often spread to humans through contaminated milk; in the United States today, *M. bovis* rarely affects humans.

Mycobacterium tuberculosis complex—the M. tuberculosis complex includes seven other TB-causing mycobacteria: M. bovis, M. africanum, M. microti, M. canetti, M. caprae, M. pinnipedii, and M. mungi. These mycobacteria are sometimes called tuberculous mycobacteria since they can cause TB disease or other diseases very similar to TB. Mycobacterium tuberculosis is the most common cause of TB in humans; it is sometimes called the tubercle bacillus.

**negative pressure**—the difference in air-pressure between two areas. A room that is under negative pressure has a lower pressure than adjacent areas, which keeps air from flowing out of the room and into adjacent rooms or areas. Negative pressure is also used to describe a nonpowered respirator.

**negative pressure isolation room**—see **airborne infection** isolation (All) room

**nontuberculous mycobacteria**—mycobacteria that do not cause TB disease and are not usually spread from person to person; one example is *M. avium*-complex

**non-U.S.-born persons**—people born outside of the United States; non-U.S.-born persons from areas of the world where TB is common (for example, Asia, Africa, Latin America, Eastern Europe, and Russia) are more likely to be infected with *M. tuberculosis* 

**nucleic acid amplification (NAA)**—a technique that amplifies (copies) DNA and RNA segments. Often used in assays to directly detect microorganisms in sputum specimens.

**panel physicians**—overseas health care providers who screen U.S. immigration applicants for TB disease

**pathogenesis**—how an infection or disease develops in the body

**peripheral neuropathy**—damage to the sensory nerves of the hands and feet, causing tingling, numbness, or pain in the hands and feet

**personal respirator**—special device designed to protect users from inhaling droplet nuclei; used in health care facilities and other settings where TB may be spread

**polymerase chain reaction (PCR)**—a type of NAA used to make many copies of a segment of DNA or RNA

**poly-resistant TB**—TB that is resistant to at least two TB treatment drugs (but not both isoniazid and rifampin, i.e., it is not the same as MDR TB)

**PPD (purified protein derivative)**—the type of tuberculin used in the Mantoux tuberculin skin test

**primary drug-resistance**—drug-resistance caused by person-to-person transmission of drug-resistant organisms

**pulmonary TB**—TB disease that occurs in the lungs typically causing a cough and an abnormal chest x-ray; pulmonary TB is usually infectious if untreated. Most TB cases reported in the United States are pulmonary cases.

**pyrazinamide (PZA)**—first-line drug for the treatment of TB disease, may cause hepatitis and other adverse reactions in some patients

**pyridoxine**—another name for vitamin B6; it is given to prevent peripheral neuropathy; should always be given to pregnant and breastfeeding women on isoniazid; and to patients with diabetes or HIV

**QuantiFERON®-TB Gold Plus (QFT-Plus)**—an interferon-gamma release assay (blood test) used to determine TB infection. The QFT-Plus measures the response of immune cells to simulated TB proteins when they are mixed with a small amount of whole blood.

**respiratory-protection controls**—the third level in the hierarchy of TB infection-control measures; used to minimize the risk for exposure to *M. tuberculosis* 

**rifabutin**—a drug used to treat TB disease; used as a substitute for rifampin (RIF) in the treatment of all forms of TB

**rifampin (RIF)**—a key drug used to treat TB disease; also used for LTBI treatment. Rifampin has several possible side effects (for example, hepatitis, turning body fluids orange, drug-drug interactions, and flu-like symptoms).

**rifapentine (RPT)**—a drug used to treat TB disease; also used in the 12-dose regimen to treat LTBI

**secondary drug-resistance**—also referred to as acquired drug-resistance; develops during TB treatment, either because the patient was not treated with the appropriate treatment regimen or because the patient did not follow the treatment regimen as prescribed

**silicosis**—a lung disease caused by inhaling silica dust, which is released by breaking rocks or is used in the production of glass and ceramics; occurs most often in mining, construction, and foundry workers

**skin test conversion**—a change in a skin test reaction from negative to positive between testing intervals

**smear**—a specimen that has been smeared onto a glass slide, stained, washed in an acid solution, and then placed under the microscope for examination; used to detect acid-fast bacilli in a specimen

**sputum**—phlegm from deep in the lungs, coughed up and collected in a sterile container for processing and examination

**surgical mask**—device worn over the nose and mouth of a person who has, or might have, infectious TB disease to prevent infectious droplet nuclei from being spread (exhaled) into the air

**susceptible**—an organism's ability to be killed by a particular drug

**symptoms of TB disease**—noticeable conditions caused by TB disease. The symptoms of pulmonary TB disease include coughing, pain in the chest when breathing or coughing, and coughing up sputum or blood. The general symptoms of TB disease (pulmonary or

extrapulmonary) include weight loss, fatigue, malaise, fever, and drenching night sweats. The symptoms of extrapulmonary TB disease depend on the part of the body that is affected by the disease.

**targeted testing**—a TB control strategy to identify persons with latent TB infection who are at high risk for developing TB disease and who would benefit from treatment

**TB risk assessment**—an initial and ongoing evaluation of the risk for transmission of *M. tuberculosis* in a particular health care setting

**TB screening**—an administrative control measure in which health care personnel are evaluated for latent TB infection (LTBI) and TB disease. TB screening includes a baseline individual TB risk assessment, a TB symptom evaluation, a TB test (e.g., a TB blood test [interferon-gamma release assay] or a tuberculin skin test), and additional evaluation for TB disease as needed.

**TB testing program**—a program in which employees and residents of a facility are periodically tested for TB; done to identify people who have TB infection and possibly TB disease and to determine whether TB is being transmitted in the facility

**transmission**—the spread of an organism, such as *M. tuberculosis*, from one person to another. The probability of transmission depends on the contagiousness of the patient, the type of environment, the length of exposure, and the susceptibility of the exposed individual.

**T-SPOT®.** *TB* **Test (T-Spot)**—an interferon-gamma release assay (blood test) used to determine TB infection; the T-Spot measures the number of T cells that secrete IFN-γ upon activation by *M. tuberculosis* antigens

**tubercle bacilli**—another name for the *Mycobacterium tuberculosis* organisms that cause TB disease

**tuberculin**—a substance made from tubercle bacilli that have been killed by heating; used to determine whether a person has TB infection. Tuberculin is not a vaccine.

**tuberculin skin test (TST)**—a test used to detect TB infection (see **Mantoux tuberculin skin test**)

**tuberculin unit**—a standard strength of tuberculin used in the United States and Canada; a strength of 5 tuberculin units is used for the Mantoux TST with PPD

tumor necrosis factor-alpha (TNF-alpha) antagonists, inhibitors, or blockers—medications used to treat inflammatory or autoimmune diseases such as rheumatoid arthritis, Crohn's disease, psoriatic arthritis, and juvenile rheumatoid arthritis

**two-step testing**—a strategy used in TB testing programs to distinguish a boosted reaction (caused by TB infection that occurred many years ago) from a reaction caused by recent infection. If a person has a negative reaction to an initial skin test, a second test is given 1 to 3 weeks later; a positive reaction to the second test probably represents a boosted reaction, not recent infection. Two-step testing is used in many TB testing programs for skin testing employees when they start their job.

**ultraviolet germicidal irradiation**—the use of special lamps that give off ultraviolet light, which kills the tubercle bacilli contained in droplet nuclei

**user seal check**—formerly called "fit check"; procedure performed to check for the proper seal of a respirator each time a respirator is put on

**ventilation systems**—air systems designed to maintain negative pressure and to exhaust the air properly; designed to minimize the spread of TB in a health care facility

**window period**—the time between a person's last exposure to infectious TB and when a TST or IGRA can reliably detect infection with *M. tuberculosis* 

**Xpert MTB/RIF assay**—a nucleic acid amplification (NAA) test that simultaneously identifies *Mycobacterium tuberculosis* complex and rifampin resistance in a sputum sample

**X-ray**—a test that produces images of the inside the body. X-ray beams pass through the body and are absorbed in different amounts depending on the density of the material they pass through. Dense materials, such as bone, show up as white on X-rays. Air in the lungs shows up as black. Fat and muscle appear as varying shades of gray.

Notes			
			_
			_

Notes		

Notes		

